Declining Risk of Sudden Death in Heart Failure
Li Shen(South China Agricultural University), John J.V. McMurray(University of Glasgow), Christopher B. Granger(Clinical Research Institute), John G.F. Cleland(University of Glasgow), Pardeep S. Jhund(Copenhagen University Hospital), John Wikstrand(Golden Jubilee National Hospital), John Kjekshus(Nuffield Health), Roberto Latini(Mario Negri Institute for Pharmacological Research), Luigi Tavazzi(Maria Cecilia Hospital), Lars Køber(University of Copenhagen), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Milton Packer(Baylor University Medical Center), Bertram Pitt(Bayer (Germany)), Michael R. Zile(Medical University of South Carolina), Scott D. Solomon(Brigham and Women's Hospital), Simona Barlera(Mario Negri Institute for Pharmacological Research), Karl Swedberg(Brigham and Women's Hospital), Aldo P. Maggioni(Health Care Foundation), Mark C. Petrie(British Heart Foundation), Henry J. Dargie(Glasgow Royal Infirmary), Brian Claggett(National Heart Lung and Blood Institute)
Cited by 500
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k